News and Announcements
BANXA (TSX-V: “BNXA”) Reports Record Growth of $55m Total Transaction Value (TTV) For January 2021
- Published February 02, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Banxa provides its clients safe, compliant access to the digital assets market, Banxa partners include major exchanges and wallets including Binance, OKEx, Huobi, Edge and Kucoin.
The company also reports that financials for the period ending December 31, 2020 will be announced March 1, 2021.
ON BEHALF OF THE BOARD OF DIRECTORS
Per: “DOMENIC CAROSA”
Domenic Carosa
Chairman (+1-888-218-6863)
For Further Information, see www.banxa.com
For further information:
Investor Relations :
North America +1 (604) 609 6169
International: +61 451 744 080
Email: [email protected]
Media Contacts:
Liam Bussell, Head of Corporate Communications,
Email: [email protected]
[Banxa latest investor presentation]
Banxa: 1 page summary – Click here
Banxa: Investor Deck – Click here
About BANXA
BANXA (TSX-V:BNXA – Banxa Holdings Inc.) is a Payment Service Provider (PSP) with a mission to build the bridge between traditional financial systems, regulation and the digital asset space. Our goal is to onboard the general public to digital currency by building a fully compliant payment infrastructure that enables simple and secure conversion of fiat currency to digital currency. (USD/CAD to BTC/ETH) Banxa has offices in Australia and the Netherlands.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
